Download BLFS Presentation – May 2015

Investor Presentation
NASDAQ:BLFS
Safe Harbor Statement
This presentation contains forward-looking statements, including, but not limited to, statements
concerning the company’s anticipated business and operations, the potential utility of and market
for its products and services, potential revenue growth and market expansion, new products, and
third party projections regarding the future market for regenerative medicine and cold chain
packaging and instrumentation services. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. These statements are based on
management’s current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ materially from those
described in the forward-looking statements, including among other things, uncertainty regarding
market adoption of products; uncertainty regarding third party market projections; market volatility;
competition; litigation; and those other factors described in our risk factors set forth in our filings
with the Securities and Exchange Commission from time to time, including our Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the
forward-looking statements contained herein or to reflect events or circumstances occurring after
the date hereof, other than as may be required by applicable law.
2 BIOPRESERVATION TOOLS
FOR CELLS, TISSUES AND ORGANS
Preservation of Biologic Material
Drug
Discovery
Solid Organs
Tissue Biopsies
Regenerative
Medicine
Tumor
Blood
Bone Marrow
Allogeneic
Transplant
Autologous
Transplant
Biobanking
4 Biopreservation Challenges
Removed from the body - cells, tissues and organs enter a
continuum of degradation – a race against time!
Ex Vivo Time
Function
Function
Viability - Quality
Viability
Survival
Survival - Quantity
Ex Vivo Time
Ex Vivo Time
Hypothermia (cold chain management) is used to preserve
biologic integrity and functional performance. Traditional
methods and tools are not optimized and offer limited
protection from preservation-induced stress, injury, and death.
5 Biopreservation Tools
Media and other
tools designed to
preserve biologics
during ex vivo
storage
Shipping products designed to
maintain stability of cells and
tissues during transportation
from patient to lab and back to
patient
Goal:
maximize
effectiveness
of biologic
based
medicine
6 BIOPRESERVATION
MEDIA
Our Biopreservation Media
Clinical grade preservation media
made per GMP – facility and QMS
certified to ISO13485
Formulated to mitigate molecular
cell stress during refrigeration and
freeze/thaw process
Serum-free, protein-free, AOF; USP
ingredients; US FDA Master Files
Patented technology; performance
superior to commercial and
homemade alternatives; also
protected by trade secrets
8 Cell Yield Comparison
Preserved
in traditional
“home brew”
Cells are
mostly
dead
Preserved
in BioLife
HypoThermosol®
Cells are
vital,
thriving
Human mesenchymal stem cells isolated from bone marrow;
condition of cells after 5 days of cold storage, then returned to
culture conditions and assayed 24 hours later
9 Better Cell Yield = Cost Reductions
Manufactured
Cell Products
Source Material
LESS
= MORE Doses
Required
Yield
Yield
Cost
LESS
Required to Achieve
Desired Therapeutic
Effect
Cost
10 Limited Shelf Life = Cost Adder
If distribution range is limited
by short shelf-life - multiple
production facilities required
Increased CAPEX requirements
Cell Factory
Cell Factory
Cell Factory
Cell Factory
Cell Factory
11 Longer Shelf Life = Lower Costs
Our products extend shelf life to support
worldwide distribution of cellular therapeutics
Reduced
CAPEX requirements
Cell Factory
12 biologistex™
Intelligent, Informed, Precise
Biologic Materials Management
Cold Chain Biologistics
Source
Material
Preservation
Media
Temperature
Controlled
Container
Cell
Factory
Patient
Temperature
Controlled
Container
Preservation
Media
Manufactured
Cell
Product
14 Current Biologistics Reality
TIME
All vaccines
and 70% of
biologics are
temperature
sensitive
Regenerative
medicine
therapies
require
precise
thermal
protection
during
shipment
Limited temp
stability of
traditional
shipping
containers;
cell viability
declines; lost
and unusable
doses
Limited use of
real-time
temperature
monitoring
and reporting
during
shipment
15 Biologistics Risks
Rx
Clinical
Administering a
thermally sensitive
biologic dose that was
exposed to unknown
temperature
excursions, packout
errors or has
exceeded it stability
period
$
Economic
Cost of scrapping
biologic source material
or manufactured cell
products
Clinical trial impact from
poor biologistics
management; lost dose,
poor shipping container
performance, temperature
excursions
16 Breakthrough Disruptive Technology
Simple, reusable, super
insulating shipping container
Smart box – integrated cellular
modem and payload monitoring
electronics
Cloud-hosted biologistics
management app
Easy packout process
evo™ Smart Shipper
17 Current Solutions Inadequate
Foam Coolers
Vacuum Panel Shipper
•  Limited performance
•  Very large footprint; heavy
•  Technology essentially
unchanged for over 25
years
•  Expensive to ship
•  Single use
•  Refrigerants must be
preconditioned to multiple
temperature ranges before
use
•  Environmental impact
•  Complicated assembly
18 Biologistex CCMSM
Cloud App
Actionable Alerts
LIMS/API
EVO # 31099282738
Alert: Delivered to St.
Luke’s Medical Center
on 5/5/2015 at 20:08
PST
19 Web App – SaaS Business Model
Biologistex CCMSM
Real-time Location
EVO # 31099282738 Alert: Package is
within 5 miles of destination as of
5/5/2015 at 21:19PST
Multiparameter Monitoring
Configurable Alerts
20 SaaS Business Model
Potential to build a base of thousands of
shippers deployed throughout the world –
each generating subscription revenue for
rental use and data access
21 OTHER SERVICES
Contract Manufacturing Services
Utilizing excess
production capacity
Niche provider of aseptic
media formulation, fill, and
finish services
Highly selective opportunities
with strong alignment with our
capabilities
23 OUR MARKETS
3 Strategic Markets
BIOBANKING
Umbilical cord
blood banks
DRUG DISCOVERY
Pharmaceutical
companies
Adult stem cell
banks
Cell suppliers
Tissue banks
Toxicity testing labs
Biorepositories
Hair transplant
physicians
REGENERATIVE
MEDICINE
Commercial cell
therapy and tissue
engineering
companies
Hospital-based stem
cell transplant
centers
University-based
clinical research labs
25 Products Used in 185 Clinical Trials
Each successful trial =
40
47
77
21
Pre-Clinical
Phase I
Phase II
Phase III
Solid Tumors
4
17
36
5
Hematologic Malignancies
8
8
11
2
Heart Disease
1
2
8
2
Stroke
0
0
4
0
Joint Disease
4
1
1
2
Vision Loss
1
1
0
0
Immune Disorders
8
9
9
2
14
9
8
8
$0.5-2M/year
in revenue
All Others
26 Biologistics Addressable Market
$500 Million Estimated Addressable Market for Shipping Containers
Specialized
Packaging
$2.6
Billion
$5.1
Billion
$4.9
Billion
$3.2
Billion
Transportation
2004
Source: IMS Health, Evaluate Pharma
2019
Source: iMarc Group, December 2013
27 Growing Demand for
Biopreservation Media
$820
Million
$345
Million
2004
Major
growth
expected from
Regenerative
Medicine
segment
2019
Source: Biopreservation Market - Global Industry Analysis, Size, Share, Growth, Trends
and Forecast, 2013 – 2019 (Transparency Market Research, April, 2014)
28 INVESTMENT
OPPORTUNITY
NASDAQ: BLFS
Complementary
tools extend shelf
life and increase
survival
of cells and tissues
IP embedded in
more than 185
clinical trials
25% annual
core products
revenue growth
$8.5M cash
and no debt
at end of Q1
30 Significant Long-Term Growth Drivers
$
Biopreservation
unmet needs
Increased
regulatory
scrutiny
Increased
commercial
risk; trial
failure
Building the Pipeline
Smart, high
performance
containers
The Internet of
Things; SaaS
Model
Regen Med
Franchise
Capturing Value
Revenue and Profit Growth; Enterprise Value
31 500+
existing customers
Products used in rapid
growth biobanking and
drug discovery markets
>185
Regenerative
medicine clinical
projects and trials
using BioLife products
New SaaS offering
will revolutionize
biologistics
management
Significant
Growth
Potential
$100M
Current production
revenue capacity
32 Investment Fundamentals
March 31, 2015
Cash and Investments $8.6M
Total Debt $0.00
Total Stockholder Equity $12.7M
Shares Outstanding 12M
3/25/14 – issued 3.6M shares at $4.30
Options 1.4M
most in the money
Warrants 7.4M
most at $4.75 – debt conversion/equity raise
Average Volume ~100,000 shares
Market Cap ~$25M
Public Float 52%
33 NASDAQ:BLFS
BioLife Solu5ons, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 For addi(onal ques(ons or comments, please contact: Michael Rice | President and CEO [email protected] | (425) 686-­‐6003 Daphne Taylor | CFO, VP -­‐ Finance & AdministraHon [email protected] | (425) 686-­‐6002 34